On September 25, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, reported the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam. Presented on September 23, the poster focused on two patient cases from Kintara’s Phase 2 study evaluating the safety and tolerability of VAL-083 when administered concurrently with radiation therapy (RT) in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM) following surgical resection (Press release, Kintara Therapeutics, SEP 25, 2023, View Source [SID1234635386]).
In the first case, a 32-year-old woman with grade four GBM (MGMT-unmethylated) received conventional radiotherapy with concurrent chemotherapy with VAL-083 followed by adjuvant VAL-083 for a total of 13 cycles of VAL-083. The patient was tumor-free and has survived more than four years as of the last follow-up in March 2023. In the second case, a 49-year-old man with grade four GBM (MGMT-unmethylated) received radiotherapy with concurrent chemotherapy with VAL-083 followed by VAL-083 as an adjuvant for a total of 12 cycles. Two years after the initial treatment with VAL-083 was discontinued, a new lesion was found, and the patient had a second resection, which revealed a grade four astrocytoma. The patient was re-treated with VAL-083 and was stable as of the last follow-up in March 2023.
A copy of the abstract can be found at View Source
A copy of the poster is available on Kintara’s website at View Source